These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 18936537

  • 1. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL, Atar D, Hanley DF.
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract] [Full Text] [Related]

  • 2. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Oparil S, Kjeldsen SE, Hedner T, Narkiewicz K.
    Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
    [No Abstract] [Full Text] [Related]

  • 3. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M.
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
    [No Abstract] [Full Text] [Related]

  • 4. New data on ONTARGET: more confusion?
    Escobar C, Echarri R, Barrios V.
    J Clin Hypertens (Greenwich); 2010 Mar; 12(3):199. PubMed ID: 20433538
    [No Abstract] [Full Text] [Related]

  • 5. [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].
    Nilsson PM.
    Lakartidningen; 2010 Mar; 105(19):1382-4. PubMed ID: 18574975
    [No Abstract] [Full Text] [Related]

  • 6. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF.
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [Abstract] [Full Text] [Related]

  • 7. Is therapy of people with chronic kidney disease ONTARGET?
    Mann JF, Tobe S, Teo KK, Yusuf S.
    Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
    Sharma A, Baliga V, TRIUMPH Study Group.
    J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
    [Abstract] [Full Text] [Related]

  • 9. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J.
    Cardiovasc J Afr; 2011 Mar; 22(4):224. PubMed ID: 21881697
    [No Abstract] [Full Text] [Related]

  • 10. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M, Böhm M.
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [Abstract] [Full Text] [Related]

  • 11. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Yu LT, Zhu J, Tan HQ, Wang GG, Teo KK, Liu LS.
    Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Proteinuria: Is the ONTARGET renal substudy actually off target?
    Ruggenenti P, Remuzzi G.
    Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S.
    Lancet; 2017 Jun 03; 389(10085):2226-2237. PubMed ID: 28390695
    [Abstract] [Full Text] [Related]

  • 18. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun 29; 148(26):50-1. PubMed ID: 16875381
    [No Abstract] [Full Text] [Related]

  • 19. [The ONTARGET trial].
    Verdecchia P, Terrosu P.
    G Ital Cardiol (Rome); 2009 Feb 29; 10(2):67-72. PubMed ID: 19348142
    [No Abstract] [Full Text] [Related]

  • 20. Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
    Weber M.
    J Hypertens Suppl; 2009 Jul 29; 27(5):S9-14. PubMed ID: 19587555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.